TransMedics Group (TMDX) to Release Quarterly Earnings on Wednesday

Key Points

• TransMedics Group is set to release its Q3 2025 earnings report on October 29th, with analysts predicting earnings of $0.37 per share and revenue of $145.33 million.
• The company's previous quarterly performance in July showed an EPS of $0.92, significantly exceeding analysts' expectations, with revenues up 37.7% year-over-year.
• TransMedics currently has a market capitalization of $4.10 billion and a consensus target price of $127.18, with a mix of buy and hold ratings from analysts.

TransMedics Group (NASDAQ:TMDX - Get Free Report) is projected to issue its Q3 2025 results after the market closes on Wednesday, October 29th. Analysts expect the company to announce earnings of $0.37 per share and revenue of $145.33 million for the quarter. TransMedics Group has set its FY 2025 guidance at EPS.Investors can find conference call details on the company's upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 4:30 PM ET.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. During the same period last year, the company earned $0.35 earnings per share. The business's revenue was up 37.7% on a year-over-year basis. On average, analysts expect TransMedics Group to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

TransMedics Group Trading Up 0.2%

Shares of TransMedics Group stock opened at $120.13 on Wednesday. The company has a market capitalization of $4.10 billion, a P/E ratio of 62.24 and a beta of 2.08. The stock has a fifty day simple moving average of $116.15 and a 200 day simple moving average of $114.35. TransMedics Group has a 12-month low of $55.00 and a 12-month high of $145.50. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Monday, August 25th. Zacks Research downgraded TransMedics Group from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 6th. Stifel Nicolaus began coverage on TransMedics Group in a research report on Thursday, September 4th. They issued a "hold" rating and a $115.00 price objective on the stock. Morgan Stanley raised their target price on TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Finally, Evercore ISI began coverage on shares of TransMedics Group in a report on Tuesday, September 16th. They issued an "outperform" rating and a $155.00 price target on the stock. Seven equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, TransMedics Group presently has an average rating of "Moderate Buy" and a consensus target price of $127.18.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. raised its stake in shares of TransMedics Group by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company's stock valued at $34,145,000 after purchasing an additional 86,721 shares during the period. First Trust Advisors LP bought a new stake in TransMedics Group during the 2nd quarter worth approximately $5,815,000. Engineers Gate Manager LP lifted its stake in TransMedics Group by 219.3% in the 2nd quarter. Engineers Gate Manager LP now owns 41,117 shares of the company's stock worth $5,510,000 after purchasing an additional 28,240 shares in the last quarter. Jump Financial LLC bought a new position in TransMedics Group in the 2nd quarter valued at $2,921,000. Finally, Baird Financial Group Inc. purchased a new position in shares of TransMedics Group during the 2nd quarter valued at $2,743,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.